About Histamine N-methyltransferase
Histamine N-methyltransferase (HNMT) is a protein
from Homo sapiens identified by UniProt accession
P50135, 292 residues long.
MolForge cross-references it against 0 known binders and
165 disease associations.
Target properties
| Protein name | Histamine N-methyltransferase |
| UniProt accession | P50135 |
| Gene | HNMT |
| Organism | Homo sapiens |
| Length | 292 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (165)
Diseases linked to this target (Open Targets).
- autosomal recessive non-syndromic intellectual disability · score 0.54
- mathematical ability · score 0.27
- smoking initiation · score 0.12
- cutaneous melanoma · score 0.10
- gut microbiome measurement · score 0.10
- systolic blood pressure · score 0.09
- non-small cell lung carcinoma · score 0.08
- diet measurement · score 0.06
- alcohol use disorder measurement · score 0.06
- attention deficit hyperactivity disorder · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P50135-F1 | alphafold | PREDICTED | 95.82 | — |
Amino-acid sequence (292 residues)
MASSMRSLFS DHGKYVESFR RFLNHSTEHQ CMQEFMDKKL PGIIGRIGDT KSEIKILSIG GGAGEIDLQI LSKVQAQYPG VCINNEVVEP SAEQIAKYKE LVAKTSNLEN VKFAWHKETS SEYQSRMLEK KELQKWDFIH MIQMLYYVKD IPATLKFFHS LLGTNAKMLI IVVSGSSGWD KLWKKYGSRF PQDDLCQYIT SDDLTQMLDN LGLKYECYDL LSTMDISDCF IDGNENGDLL WDFLTETCNF NATAPPDLRA ELGKDLQEPE FSAKKEGKVL FNNTLSFIVI EA
Explore Histamine N-methyltransferase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets